Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

Subcutaneous injection of liquid and foamed polidocanol: extravasation is not responsible for skin necrosis during reticular and spider vein sclerotherapy.

Schuller-Petrović S, Pavlović MD, Neuhold N, Brunner F, Wölkart G.

J Eur Acad Dermatol Venereol. 2011 Aug;25(8):983-6. doi: 10.1111/j.1468-3083.2010.03873.x. Epub 2010 Oct 15.

PMID:
21740464
2.

Sclerotherapy of varicose veins with polidocanol based on the guidelines of the German Society of Phlebology.

Rabe E, Pannier F.

Dermatol Surg. 2010 Jun;36 Suppl 2:968-75. doi: 10.1111/j.1524-4725.2010.01495.x.

PMID:
20590702
3.

The French polidocanol study on long-term side effects: a survey covering 3,357 patient years.

Guex JJ, Schliephake DE, Otto J, Mako S, Allaert FA.

Dermatol Surg. 2010 Jun;36 Suppl 2:993-1003. doi: 10.1111/j.1524-4725.2009.01407.x.

PMID:
20590706
4.

Cutaneous necrosis, telangiectatic matting, and hyperpigmentation following sclerotherapy. Etiology, prevention, and treatment.

Goldman MP, Sadick NS, Weiss RA.

Dermatol Surg. 1995 Jan;21(1):19-29; quiz 31-2. Review.

PMID:
7600016
5.

Sclerotherapy: a study comparing polidocanol in foam and liquid form.

Uncu H.

Phlebology. 2010 Feb;25(1):44-9. doi: 10.1258/phleb.2009.008064.

PMID:
20118346
6.

Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results.

Hamel-Desnos C, Desnos P, Wollmann JC, Ouvry P, Mako S, Allaert FA.

Dermatol Surg. 2003 Dec;29(12):1170-5; discussion 1175.

PMID:
14725657
7.
8.

Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up.

Ouvry P, Allaert FA, Desnos P, Hamel-Desnos C.

Eur J Vasc Endovasc Surg. 2008 Sep;36(3):366-70. doi: 10.1016/j.ejvs.2008.04.010. Epub 2008 Jun 3.

9.

Migraine ophthalmique with reversible scotomas after sclerotherapy with liquid 1% polidocanol.

Künzlberger B, Pieck C, Altmeyer P, Stücker M.

Dermatol Surg. 2006 Nov;32(11):1410-3. No abstract available.

PMID:
17083597
10.
11.
12.

The Australian polidocanol (aethoxysklerol) study. Results at 2 years.

Conrad P, Malouf GM, Stacey MC.

Dermatol Surg. 1995 Apr;21(4):334-6; discussion 337-8.

PMID:
7728486
13.

Telangiectasias resistant to sclerotherapy are commonly connected to a perforating vessel.

Schuller-Petrović S, Pavlović MD, Schuller S, Schuller-Lukic B, Adamic M.

Phlebology. 2013 Sep;28(6):320-3. doi: 10.1258/phleb.2012.012019. Epub 2013 May 6.

PMID:
22865418
14.

Visual disturbance following sclerotherapy for varicose veins, reticular veins and telangiectasias: a systematic literature review.

Willenberg T, Smith PC, Shepherd A, Davies AH.

Phlebology. 2013 Apr;28(3):123-31. doi: 10.1177/0268355513486745. Review.

PMID:
23761921
15.

Polidocanol for endovenous microfoam sclerosant therapy.

Eckmann DM.

Expert Opin Investig Drugs. 2009 Dec;18(12):1919-27. doi: 10.1517/13543780903376163. Review.

16.
17.
18.

Stroke after varicose vein foam injection sclerotherapy.

Forlee MV, Grouden M, Moore DJ, Shanik G.

J Vasc Surg. 2006 Jan;43(1):162-4.

19.

A randomized trial comparing 2 doses of polidocanol sclerotherapy for hydrocele or spermatocele.

Jahnson S, Sandblom D, Holmäng S.

J Urol. 2011 Oct;186(4):1319-23. doi: 10.1016/j.juro.2011.06.005. Epub 2011 Aug 17.

PMID:
21849198
20.

Efficacy and safety of sclerotherapy with polidocanol foam in comparison with fluid sclerosant in the treatment of first-grade haemorrhoidal disease: a randomised, controlled, single-blind, multicentre trial.

Moser KH, Mosch C, Walgenbach M, Bussen DG, Kirsch J, Joos AK, Gliem P, Sauerland S.

Int J Colorectal Dis. 2013 Oct;28(10):1439-47. doi: 10.1007/s00384-013-1729-2. Epub 2013 Jun 18.

PMID:
23775099

Supplemental Content

Support Center